BACKGROUND: Cancer patients have an increased risk of thrombosis. Tissue factor (TF)
antigen and TF activity associated with microparticles in plasma are elevated in patients with …

In a previous study [1], we found that the tissue factor (TF) activity of microparticles (MP)
isolated from platelet-poor plasma (MP-TF activity) was markedly increased in patients with …

Cancer patients exhibit a high rate of thromboembolism (VTE). In this study, we analyzed
levels of microparticle (MP) tissue factor (TF) activity in cancer patients with or without VTE …

A prothrombotic state is one of the hallmarks of malignancy and a major contributor to
morbidity and mortality in cancer patients. Tissue factor (TF) is often overexpressed in …

INTRODUCTION: Elevated levels of tissue factor positive (TF+) microparticles (MPs) are
observed in plasma from a variety of patients with an increased risk of thrombosis. We and …

Patients with cancer have an increased risk for venous thrombosis. Interestingly, different
cancer types have different rates of thrombosis, with pancreatic cancer having one of the …

T hrombotic events are the major complication in cancer patients, which contribute
significantly to the patients' morbidity and mortality. Upregulation of tissue factor (TF), the …

Background: Tissue factor (TF) expression by tumors contributes to tumor growth. Release of
TF‐positive microparticles (MPs) may contribute to venous thromboembolism (VTE) …

Tissue factor (TF) plays a critical role in tumour growth and metastasis, and its enhanced
release into plasma in association with cellular microparticles (MPs) has recently been …

The pathogenesis of hypercoagulability in cancer is not entirely understood. We
hypothesized that in cancer patients circulating tissue factor-positive microparticles (TF+ …